ABSTRACT Background Low vitamin D intake and levels have been associated with increased joint symptoms in some observational studies but the findings are mixed and evidence from randomized trials sparse.
Results At baseline, total calcium and vitamin D intakes from diet and supplements were similar in the two randomization groups. In addition, both joint pain (reported by 73%) and joint swelling (reported by 34%) were commonly reported and comparable in the supplement and placebo groups. Two years after randomization, no statistically significant differences between supplement and placebo groups were seen for joint pain frequency (74.6% compared with 75.1% [P¼0.79] for supplement and placebo groups, respectively) or joint swelling frequency (34.6% compared with 32.4% [P¼0. 29] , respectively) or in severity scores for either outcome. Subgroup analyses suggested study participants also using nonprotocol calcium supplements at study entry may have less joint pain with supplement group randomization (interaction P¼0.02).
Conclusions Joint symptoms are relatively common in postmenopausal women.
However, daily supplementation with 1,000 mg calcium carbonate and 400 IU vitamin D-3 in a randomized, placebo-controlled clinical trial setting did not reduce the selfreported frequency or severity of joint symptoms. 
S EVERE VITAMIN D DEFICIENCY CAN LEAD TO JOINT disorders
1 but reports on the influence of vitamin D intake and status on joint symptoms have been mixed. Both low vitamin D intake [2] [3] [4] and low 25-hydroxyvitamin D levels, [5] [6] [7] as measures of vitamin D status, have been associated with increased joint pain. However, vitamin D status has been associated with knee osteoarthritis in only some 2, 5, 7 but not all 4, [8] [9] [10] observational study reports. In addition, reports from full-scale randomized trials are sparse. 11 To address this issue, in post hoc analyses we examined the influence of calcium and vitamin D supplementation (CaD) on joint symptoms in a randomly identified subgroup of postmenopausal women participating in the Women's Health Initiative (WHI) Calcium Plus Vitamin D Supplement randomized, placebo-controlled clinical trial.
METHODS
The WHI program includes four clinical trials (two hormone therapy [HT] trials, a dietary modification [DM] trial, and a CaD trial) and an observational study. For the WHI clinical trials, postmenopausal women aged 50 to 79 years with life expectancy !3 years, no personal breast cancer history, and no other cancer within 10 years were eligible. The HT and DM trials had additional eligibility requirements largely based on medical history. Women participating in the WHI HT trials 13, 14 or WHI DM 15 trial were invited to enroll in an additional randomized, placebo-controlled trial evaluating CaD at their first or second annual follow-up main trial visit. 16, 17 For the CaD trial, additional exclusions included hypercalcemia, history of kidney stones, and current corticosteroid or calcitriol use. Personal use of calcium (no upper limit) and vitamin D was allowed during the study period. The upper limit for allowed personal vitamin D initially was 600 IU daily, which was subsequently increased to 1,000 IU daily during the study course. 17 Eligible women who entered the CaD trial were randomly assigned, in a double-blind fashion, to receive active supplement or placebo stratified according to clinical center and calcium and vitamin D supplement containing calcium carbonate (500 mg as elemental calcium) with vitamin D-3 (200 IU) or matching placebo was taken twice daily (all from GlaxoSmithKline Consumer Healthcare). Study pills were discontinued after development of kidney stones; hypercalcemia; kidney dialysis; and calcitriol use, which causes a greater hypercalcemia risk than other vitamin D compounds.
Details of the eligibility and conduct of the HT and DM trials have been reported. [13] [14] [15] We now report on joint symptom outcomes in a subset of CaD trial participants. The participant flow through the WHI clinical trial to arrive at the study population with joint symptom assessment is outlined in Figure 1 .
From the 36,282 CaD clinical trial participants, a 6% subsample of 2,185 participants for the current study was randomly identified from those who were randomized at their first annual visit for the main trial and who had information collected during follow-up on joint symptoms. The sampling was done on the entire clinical trial population (n¼68,132) with sixfold higher odds of selection for nonwhite participants, and a sampling rate of 8.6% in the HT trials and 4.3% in the DM trial, resulting in a 6% overall sample. There was not a specific sampling target for the CaD trial because the women in that trial were also in a HT and/or DM trial. 16 It was planned to assess joint symptoms at baseline and after 2 years in the identified subgroup. Among these 2,185 women, 242 had missing information on joint symptoms or for other variables at Year 2 and 32 (1.5%) died or dropped out resulting in a study population of 1,911.
Details of the eligibility and conduct of the CaD trial have also been reported. 12, 17 The trial completed the planned intervention duration of mean 7 years of follow-up and calcium and vitamin D supplement effects on hip fracture as the primary study endpoint 17, 18 and colorectal cancer 18 and breast cancer, 19, 20 as secondary endpoints, have been published. The described clinical trial had institutional review board approval from all participating institutions and written informed consent was obtained from all participants. Statistical analyses and data management were conducted at the WHI Clinical Coordinating Center.
Dietary supplement data was collected during in-person clinic visits. Women brought their supplement bottles to the baseline clinic visit and annually thereafter. A standardized interviewer-administered form was used to collect information on multivitamins and single supplements. Staff members directly transcribed the ingredients for each supplement and asked participants about frequency and duration of use. A validity study of these procedures found correlations with photocopied labels ranged from 0.8 to 1.0. 21, 22 Prescription medication use was similarly determined by in-person review of medication containers. All reported medications were matched to the Master Drug Data Base (Medi-Span).
A self-assessment food frequency questionnaire (FFQ) specifically designed for WHI 23 was used to assess dietary intake during the previous 3 months at entry into the WHI HT or DM trials. 23 DM trial participants also had the FFQ administered at Year 1, coinciding with entry into the CaD trial. For non-DM participants, the baseline vitamin D intake at entry into the HT trials, which was 1 year before entry into the CaD trial, was used for baseline analyses. For DM participants, dietary vitamin D at baseline was correlated to Year 1 values (correlation coefficient P<0.0001). Total daily calcium intake at baseline was defined as the sum of the dietary intake (assessed with the use of a modified Block FFQ) 23 and the average daily self-reported intake of elemental calcium from supplements and from prescription medications during the previous 2 weeks. Total vitamin D intake was similarly determined reflecting not only dietary vitamin D intake (largely from fortified dairy products and fatty fish) but also vitamins D supplement use. Information on physical activity was collected by questionnaire regarding walking outside the house and recreational physical activity, including frequency, duration, and intensity. This information was used to generate metabolic equivalent values. 24 Measurements of height and weight were made in the clinic to permit body mass index (BMI) determinations.
Clinical outcomes were determined at annual clinic visits and semiannual contacts. Annual clinic visits included counting or weighing returned pills as an adherence measure. Joint pain and swelling was assessed by questionnaire collected at initial WHI clinical trial entry (1 year before the CaD trial randomization), 1 year after entry and again after 2 years of participation in the CaD study. Joint pain was assessed as yes/ no; severity was assessed as none¼0, mild¼1, moderate¼2, and severe¼3. Joint swelling was assessed similarly.
Statistical Analyses
The analysis of joint symptoms utilized results from the 1,911 randomized participants with available baseline and follow-up information. c 2 Tests were used to compare the baseline characteristics between randomization groups. The frequency and severity of joint symptoms (pain and swelling) were compared by randomization group (active vs placebo) and logistic regression models were used to compare the occurrence of any symptoms vs none, both unadjusted and adjusted for age and race/ethnicity. Similarly, the average symptom score, where none¼0 and severe¼3, was compared in unadjusted and adjusted linear regression models. The difference in scores between follow-up and baseline were computed and analyzed the same way. The influence of randomization to calcium and vitamin D supplementation or placebo on joint symptoms was examined in six subgroups (BMI, physical activity, nonprotocol calcium supplement use, nonprotocol vitamin D supplement use, race/ethnicity, and HT use [randomization to the intervention group for HT trial participants and current HT use for women not in HT trials]). In these analyses, odds ratios and 95% CIs for effect of CaD on joint pain are estimated from a logistic regression model adjusted for linear age and race/ ethnicity. P values testing for interaction separately for each subgroup are from models, including terms for the main effects for CaD supplementation and the subgroup, plus their interaction. For testing, age and BMI (log-transformed) were modeled as linear terms; physical activity was coded 0 to 4, representing the five quintile categories of physical activity. Less than one statistically significant interaction test (P<0.05) would be expected based on chance alone.
All analyses were performed using SAS statistical software, version 9.1.3 (2007, SAS Institute Inc). All P values are twosided and P<0.05 was regarded as significant. The WHI study is registered with clinicaltrials.gov, no. NCT000000611.
RESULTS
In the subgroup of 1,911 clinical trial participants with serial joint symptom assessment, demographic characteristics, health behaviors, and medical history were well balanced between randomization groups. Considering all participants, mean age at entry was 62 years with a mean BMI of 29. As a result of oversampling for minorities, nearly half of participants were nonwhite (Table 1) .
At baseline, total calcium and vitamin D intakes, reflecting both dietary intake and supplement use, were similar in the two randomization groups with nonprotocol vitamin D supplement use !400 IU daily reported by 42% of the placebo group and 40% of the supplement group, respectively (Table 1) . During the course of the study, nonprotocol calcium and vitamin D supplements were permitted and their use was similar between randomization groups. At 2 years, median nonprotocol calcium use was 40 mg/day and nonprotocol vitamin D supplement was being used by 48% of participants with mean dose of 199 IU and median dose of 0 IU/day. As a result, total vitamin D intake (diet plus nonprotocol supplement plus protocol supplement) was 773 IU, mean and 724 IU, median in the supplement group and 367 IU, mean and 312 IU, median in the placebo group after 2 years. At that time, total calcium intake was 2,031 mg, mean and 1,877 mg, median in the supplement group and 1,041 mg, mean and 920 mg, median in the placebo group.
Adherence to the randomly assigned calcium and vitamin D supplement or placebo (defined as use of 80% or more of study medication) ranged from 60% to 63% during the first 3 years with an additional 13% to 21% taking at least half of their study pills with small difference between randomization groups.
Joint pain and swelling at baseline entry into the CaD trial was closely comparable in the two randomization groups with more than 70% of supplement and placebo group participants reporting joint pain and about a third reporting joint swelling. Joint symptoms at baseline and after 2 years on CaD or placebo are shown by randomization group in Table 2 . After 2 years, no statistically significant difference between supplement and placebo groups were seen for joint pain frequency (74.6% vs 75.1%, for supplement and placebo groups, respectively; P¼0.79) or joint swelling frequency (34.6% vs 32.4%, respectively; P¼0.29). The severity of joint pain or joint swelling also was similar in the supplement and placebo groups after 2 years ( Table 2) .
The potential for interaction with age, BMI, physical activity, nonprotocol calcium and vitamin D use, race/ethnicity, and HT on the association between joint pain and randomization group was examined (Figure 2 ). No interaction with age, BMI, race/ethnicity, or physical activity was seen. The CIs for all but white and black women are very wide and are essentially noninformative. There was a suggestion of a favorable effect of CaD on joint pain in hormone therapy users and women aged 70 to 79 years, but the interactions were not statistically significant (interaction P values 0.07 and 0.09, respectively). Participants who were also using nonprotocol calcium supplements at entry had less joint pain when randomized to the supplement compared to the placebo group (interaction P¼0.02), whereas no significant interaction was seen with nonprotocol vitamin D supplement use at entry.
DISCUSSION
Joint symptoms were common in this population of postmenopausal women. However, in the setting of a Statistical tests comparing CaD treatment randomization included P values from either a logistic regression model (none/any) or linear regression model (average) demonstrated no statistically significant difference comparing CaD to placebo use at baseline, after 2 years of intervention, or in the change from baseline to Year 2. Tests were performed both unadjusted and adjusted for age and race/ethnicity. randomized, placebo-controlled, clinical trial, calcium (1,000 mg/day as elemental calcium) plus vitamin D supplementation (400 IU/day of D-3) did not reduce the frequency or severity of joint symptoms of postmenopausal women compared with placebo. Thus, women using CaD at this dose should not anticipate joint symptom relief.
Severe vitamin D deficiency can result in osteomalacia characterized by proximal muscle weakness and bone loss 1 but reports on the association between vitamin D intake and/or levels with joint symptoms have been mixed. Whereas some observational studies suggest a threshold of 25-hydroxyvitamin D levels above 36 ng/mL (89.86 nmol/L) are needed for lower osteoarthritis risk, 2,7 others find no association. 4, [8] [9] [10] In previously reported analyses in WHI clinical trial participants, women with low serum 25-hydroxyvitamin D levels did have statistically significantly higher joint pain scores compared with women with higher 25-hydroxyvitamin D levels but the threshold (seen in the lowest quintile) was a much lower 12 ng/mL 6 (29.95 nmol/L) than found in some prior studies. 2, 7 The inconsistent observational study findings [25] [26] [27] support the need for randomized clinical trials to definitively address this issue.
Only one other full-scale, randomized clinical trial has addressed the issue of joint pain and vitamin D supplementation but studied a different population with a different intervention. McAlindon and colleagues 11 entered 146 men and women with symptomatic osteoarthritis of the knee with serial cartilage volume loss documented by magnetic Figure 2 . Estimated effects of calcium and vitamin D supplementation on the risk of joint pain according to selected baseline characteristics. In these analysis, odds ratios and 95% CIs for effect of calcium and vitamin D supplementation on joint pain are estimated from a logistic regression model adjusted for linear age and race/ethnicity. P values testing for interaction separately for each subgroup are from models including terms for the main effects for calcium and vitamin D supplementation and the subgroup, plus their interaction. For testing, age and body mass index (log-transformed) were modeled as linear terms; physical activity was coded zero to four representing the five categories of physical activity. Current hormone therapy reflects use at baseline if randomized to the dietary modification trial only or randomized to active vs placebo if randomized to one of the hormone therapy trials. Calcium supplementation and vitamin D supplementation reflects nonprotocol use at study entry. E-alone¼estrogen alone. EþP¼estrogen plus progestin. resonance imaging. Participants were randomized to a higher dose, vitamin Deonly intervention (2,000 IU/day daily oral vitamin D-3 with escalation to target 25-hydroxyvitamin D serum levels >36 ng/mL [89.86 nmol/L]) or placebo. After 2 years, no reduction in knee pain or cartilage volume loss was seen with the supplementation. 11 As one possible explanation for the null findings, the authors suggested that the severity of the structural damage might have been too severe to expect reversal. Two smaller randomized trials, entering between 50 and 60 participants, also evaluated higher-dose vitamin D regimens (50,000 IU vitamin D-2 weekly for 3 or 4 months) but reported no significant influence on musculoskeletal pain. 28, 29 In our study, we addressed, for the first time in a full-scale, randomized clinical trial setting, the clinically relevant question regarding whether postmenopausal women using calcium and vitamin D supplements in currently recommended dosages would experience any favorable effect on joint pain or swelling, common symptoms in postmenopausal women.
The vitamin D-3 dosage of 400 IU/day used in the WHI trial followed the Institute of Medicine recommendations that were available during the course of the trial. 30 The Institute of Medicine recently updated their guideline and increased their recommended dietary allowance for vitamin D intake moderately to 600 IU/day for those aged 70 years and 800 IU/day for those aged 71 years and older. 31 However, because about half of the WHI study participants were taking additional nonprotocol vitamin D, 19 many women in the supplement group had substantially greater vitamin D intakes. Based on the first comprehensive study of dose response to vitamin D supplementation in postmenopausal women in a recently reported randomized trial, Gallagher and colleagues 32 concluded that a vitamin D-3 dosage of 600 IU/day would be sufficient to meet the nutrition requirements of nearly all (97.5%) healthy persons. Because the mean total vitamin D dose in the WHI supplement randomization group was 773 IU/day, including diet and protocol and nonprotocol supplement use, we found no influence of the currently recommended vitamin D intake on joint symptoms in supplement group participants in this trial. Although the influence of higher-dose supplementation with calcium and vitamin D on joint symptoms are not known, current evidence does not support dosages exceeding the recent Institute of Medicine recommendation at this time. 31 The statistically significant, positive interaction that was seen between baseline nonprotocol calcium use and joint pain benefit from protocol CaD was an unexpected finding. This result could reflect the play of chance or self-selection bias, especially because calcium has not historically been linked to joint symptoms. Alternatively, one could speculate that a calcium threshold level is required for vitamin D to favorably influence joint symptoms. In any case, the calcium result seen in a subgroup analyses clearly requires further study.
Study strengths include the size of the well characterized study population; the inclusion, by design, of a substantial minority population; joint symptom information collected within the context of a randomized clinical trial of calcium and vitamin D supplement use; and serial joint symptom assessment using a quantitative instrument that was prospectively applied. Study limitations include the fact that joint symptoms were not prospectively identified study endpoints and, although randomly identified, only a subset of participants in the trial was included. Also, the joint symptom scale used has not been compared with other instruments or been formally validated. Although joint symptoms in postmenopausal women have a range of etiologies (commonly osteoarthritis but also rheumatoid arthritis and other autoimmune diseases as well as fibromyalgia and other causes), a quantitative, prospective serial assessment of the presence and severity of joint pain and swelling provides clinically relevant outcome information. Allowing nonprotocol calcium and vitamin D use is another limitation. However, the difference in intakes between groups was sufficient to increase bone mineral density overall and decrease hip fracture in older participants and in adherent participants in the active intervention group. 15 The influence of taking calcium and vitamin D supplements individually on joint symptoms cannot be determined because both were provided combined in a single pill in this trial.
The findings from the current WHI randomized, placebocontrolled clinical trial evaluating CaD do not support use of calcium and vitamin D for joint symptom reduction at the dosage examined. These findings do not speak against current recommendations for vitamin D intakes for bone health and fracture risk reduction.
